[{"Assets_0_Q2_USD":1066861000.0,"CommonStockSharesOutstanding_0_Q2_shares":91536000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-48325000.0,"NetIncomeLoss_1_Q2_USD":51338000.0,"NetIncomeLoss_2_Q2_USD":-50777000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":91389000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":91226000.0,"StockholdersEquity_0_Q2_USD":483706000.0,"EarningsPerShareBasic_1_Q2_USD":0.56,"EarningsPerShareBasic_2_Q2_USD":-0.56,"Ticker":"NBIX","CIK":"914475","name":"NEUROCRINE BIOSCIENCES INC","OfficialName":"Neurocrine Biosciences Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"9338885763.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20190729"}]